Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: declining revenue, increased operating expenses, and a slight rise in net loss, indicating financial struggles. The shift from R&D to commercial efforts could hinder future innovation. Additionally, challenges in payer engagement and European market entry pose risks. While management remains optimistic about partnerships and Medicaid coverage, the lack of specific metrics and timelines, coupled with potential delays, adds uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Key Financial Performance
Revenue $14,000 compared to $38,000 in the first quarter of 2025, reflecting a decrease. The decline is attributed to the timing and nature of the geographically targeted commercialization strategy and ongoing efforts to build advocacy and awareness following the PRIME publication.
Operating Expenses $9.4 million, up slightly from $9.3 million in the prior year period. This increase aligns with expectations and reflects disciplined cost management alongside continued investment in evidence generation, regulatory preparation, and advocacy activities.
Research and Development Expenses $3.0 million compared to $3.3 million in 2025, showing a decrease. The reduction is due to the PRIME study now being published, leading to a shift in focus towards activities that directly drive commercialization and awareness building.
Selling, General and Administrative Expenses $6.3 million versus $5.9 million in the prior year, indicating an increase. This rise reflects the transition from clinical stage investments toward targeted commercial initiatives and strategic headcount.
Net Loss $8.4 million compared to $8.2 million in the first quarter of 2025, showing a slight increase. This is consistent with the company's measured commercialization strategy and ongoing investments in advocacy and awareness.
Cash, Cash Equivalents, and Available-for-Sale Securities $86.8 million as of March 31, 2026. This reflects the company's financial position and its ability to fund operations through significant adoption and commercial milestones through 2029.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PreTRM Test: Focused on building awareness and education among clinicians and stakeholders. Highlighted at key clinical forums like SMSM and ACOG meetings. Featured in podcasts and media to increase awareness, including a podcast with Hailey Bieber and upcoming episodes.
Market Expansion in Europe: Progress towards commercialization readiness in Europe with a midyear submission of CE Marking dossier. Engagement with European advisory group to align on clinical utility and evidence requirements.
U.S. Market Expansion: Launched a third partnership program reaching over 350 providers across 3 states. Engaged in discussions with 13 payers across 15 states to deepen relationships and expand access.
Operational Efficiencies: Realigned resources to prioritize commercialization and medical activities. Reduced R&D and G&A expenses, resulting in $10 million annual savings. Extended cash runway through 2029.
Advocacy and Policy Engagement: Launched a letter-writing campaign to encourage Medicaid reimbursement for PreTRM. Engaged with stakeholders to support legislative initiatives for earlier identification and prevention of preterm births.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue decline: Revenue for the quarter was $14,000 compared to $38,000 in the first quarter of 2025, reflecting challenges in the timing and nature of the geographically targeted commercialization strategy.
Operating expenses: Operating expenses for the quarter were $9.4 million, slightly up from $9.3 million in the prior year, indicating cost pressures despite efforts to manage expenses.
Net loss: Net loss for the quarter was $8.4 million compared to $8.2 million in the first quarter of 2025, highlighting ongoing financial challenges.
Commercialization strategy risks: The company’s geographically targeted commercialization strategy has resulted in modest and uneven revenue, with significant adoption cycles expected to take time.
Reimbursement and payer engagement: The company is engaged in discussions with 13 payers across 15 states, but reimbursement remains a challenge, potentially delaying broader adoption and revenue growth.
R&D expense reduction: Research and development expenses are being reduced, which could impact future innovation and product development.
Advocacy and policy hurdles: Efforts to engage with state Medicaid programs and policymakers are ongoing but may face delays or resistance, impacting reimbursement and adoption.
European market entry: Progress towards commercialization readiness in Europe is ongoing, but regulatory and clinical stakeholder alignment could pose challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Revenue in 2026 is expected to remain modest and uneven due to the ongoing focus on reimbursement, awareness, and advocacy campaigns. Increasing pull-through is anticipated later in the year and into 2027.
Capital Deployment: The company has realigned resources to prioritize investments in payer engagement, market access, and clinical adoption. Operating expenses are expected to decrease by nearly $10 million annually, with the majority of savings realized in 2027 and beyond. Existing cash and cash equivalents are projected to fund operations through 2029.
Commercialization Strategy: The company is focusing on building sustainable access points and referral pathways to support long-term volume and revenue. Active discussions with 13 payers across 15 states are ongoing, with a concentrated approach to drive meaningful implementation and adoption.
European Market Entry: The company remains on track for a midyear submission of its CE Marking dossier, with commercialization readiness progressing in Europe. Engagement with European advisory groups and regulators continues to align around clinical utility and implementation considerations.
Future Publications and Studies: Several additional PRIME sub-analyses are expected to be published in 2026, including a health economic study, Medicaid population outcomes, and a focused analysis of first-time moms. These publications aim to strengthen the clinical and economic foundation for adoption.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide details on the profile of the third partner program and how it compares to the first two? Also, what is the required cadence to achieve the goal of 5 to 7 partner programs this year?
A:The third partner program is being launched this quarter, following a cadence of roughly one program per quarter. Each program involves a combination of payer and provider groups to ensure seamless integration into physician office workflows. The company is on track with its goal, with 13 payers in 15 states currently engaged, up from 10 payers in 13 states last quarter. The programs are designed to ensure fast recruitment and delivery of tests, with quarterly progress reported to state Medicaid agencies.
Q:Are there any KPIs being measured for new reps, such as tests per rep per month, for the second half of the year?
A:The company is monitoring metrics like the number of tests per month per rep but is not yet ready to report these metrics publicly. They are cautiously optimistic and will report once steady progress is observed.
Q:What prompted the shift to a more direct commercial effort and reduced R&D focus?
A:The shift was driven by two factors: reduced internal demand for R&D and clinical operations capacity following the completion of the PRIME project, and increased external demand for partnerships in developing new tests. The company is strategically reallocating resources to focus on commercialization and leveraging its proteomics platform for collaborative opportunities.
Q:Is the company still on track for low single-digit thousand volumes this year?
A:While the company does not report order volumes, the assumption of low single-digit thousand volumes is not unreasonable. They will report on volumes once steadiness is observed.
Q:When can the first Medicaid program potentially turn into a positive coverage decision?
A:The timeline for a positive coverage decision is approximately two years from the program's start. This includes 6 months for setup, 9-12 months for recruitment, 4-5 months for patient delivery, and additional time for data collection and analysis. The company expects a decision by early 2027, with ongoing advocacy efforts to expedite the process.
Q:Review of Unclear Management Responses
A:Management avoided providing specific metrics or timelines for new rep productivity and order volumes, citing the need to observe steady progress before reporting. Additionally, while they outlined a general timeline for Medicaid program coverage decisions, they acknowledged potential delays due to data complexities.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACOG
Annual
Austin
Journal
MD podcast
Maternal Fetal
Medicine
PreTRM test
RD
SMSM
Women Health
access PreTRM
access adoption
access point
advocacy
alignment
base
birth prevention
care system
discussion
education
effort awareness
engagement effort
episode
foundation term
host
identification
implementation
intervention
interview
letter
level
point pathway
policymakers
progress effort
provider
requirement
strategy
survey
track
understanding
SERA Transcript
Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals several concerns: declining revenue, increased operating expenses, and a slight rise in net loss, indicating financial struggles. The shift from R&D to commercial efforts could hinder future innovation. Additionally, challenges in payer engagement and European market entry pose risks. While management remains optimistic about partnerships and Medicaid coverage, the lack of specific metrics and timelines, coupled with potential delays, adds uncertainty. These factors suggest a negative sentiment, likely impacting the stock price negatively in the short term.
Sera Prognostics, Inc. (SERA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call reflects mixed sentiments. While there are positive aspects like disciplined expense management and promising partner programs, the company faces significant commercialization challenges and financial losses. The Q&A section indicates some optimism with stakeholder engagement and strategic partnerships, yet uncertainties in payer coverage and market access persist. The financial metrics reveal modest revenue and ongoing losses, with a stable cash position but slow growth. These factors balance out, leading to a neutral stock price prediction in the short term.
Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.
Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call highlights several concerns: a decline in net revenue, high operating expenses, and challenges in regulatory and reimbursement approvals. The Q&A reveals delays in guideline inclusion and vague responses on sales force expansion. Despite plans for European market entry, the financial strain and uncertainties overshadow potential growth. The stock price is likely to experience a negative reaction in the short term due to these factors.
SERA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
